ZA200100793B - Methods of using a somatostatin analogue. - Google Patents
Methods of using a somatostatin analogue. Download PDFInfo
- Publication number
- ZA200100793B ZA200100793B ZA200100793A ZA200100793A ZA200100793B ZA 200100793 B ZA200100793 B ZA 200100793B ZA 200100793 A ZA200100793 A ZA 200100793A ZA 200100793 A ZA200100793 A ZA 200100793A ZA 200100793 B ZA200100793 B ZA 200100793B
- Authority
- ZA
- South Africa
- Prior art keywords
- disease
- syndrome
- cys
- pharmaceutical composition
- condition
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 14
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title description 5
- 229940075620 somatostatin analogue Drugs 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 18
- 201000000052 gastrinoma Diseases 0.000 claims description 15
- 206010012735 Diarrhoea Diseases 0.000 claims description 14
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 claims description 12
- 208000009311 VIPoma Diseases 0.000 claims description 11
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 10
- 206010006895 Cachexia Diseases 0.000 claims description 9
- 206010041101 Small intestinal obstruction Diseases 0.000 claims description 9
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims description 9
- 201000008980 hyperinsulinism Diseases 0.000 claims description 9
- 206010027191 meningioma Diseases 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 8
- 208000007232 portal hypertension Diseases 0.000 claims description 8
- 230000000291 postprandial effect Effects 0.000 claims description 8
- 206010003445 Ascites Diseases 0.000 claims description 7
- 201000002980 Hyperparathyroidism Diseases 0.000 claims description 7
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 7
- 208000027868 Paget disease Diseases 0.000 claims description 7
- 206010033635 Pancreatic pseudocyst Diseases 0.000 claims description 7
- 208000027202 mammary Paget disease Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000014311 Cushing syndrome Diseases 0.000 claims description 6
- 206010020584 Hypercalcaemia of malignancy Diseases 0.000 claims description 6
- 208000001953 Hypotension Diseases 0.000 claims description 6
- 206010033664 Panic attack Diseases 0.000 claims description 6
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims description 6
- 159000000021 acetate salts Chemical class 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 206010060865 duodenogastric reflux Diseases 0.000 claims description 6
- 208000008750 humoral hypercalcemia of malignancy Diseases 0.000 claims description 6
- 230000036543 hypotension Effects 0.000 claims description 6
- 208000002780 macular degeneration Diseases 0.000 claims description 6
- 208000019906 panic disease Diseases 0.000 claims description 6
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 206010039710 Scleroderma Diseases 0.000 claims description 5
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 5
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 150000001945 cysteines Chemical class 0.000 claims description 3
- 206010061876 Obstruction Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 29
- 108010021336 lanreotide Proteins 0.000 description 28
- 229960002437 lanreotide Drugs 0.000 description 28
- 239000000203 mixture Substances 0.000 description 18
- 239000012730 sustained-release form Substances 0.000 description 9
- 238000013268 sustained release Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 108010056088 Somatostatin Proteins 0.000 description 4
- 102000005157 Somatostatin Human genes 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229960000553 somatostatin Drugs 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 208000023328 Basedow disease Diseases 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 206010036049 Polycystic ovaries Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 1
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 208000000713 Nesidioblastosis Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036832 Prolactinoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- -1 e.g. Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000035877 hyperamylinemia Effects 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012731 long-acting form Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000028893 postprandial hypotension Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
METHODS OF USING A SOMATOSTATIN ANALOGUE
3 Background of the Invention
The present invention is directed to a method of treating one or more of the following diseases and/or conditions in a patient in need thereof, which comprises the administration of the compound of the formula H-B-D-Nal-Cys-
Tyr-D-Trp-Lys-Val-Cys-Thr-NH, (also known as lanreotide), where the two
Cysteines are bonded by a disulfide bond, or a pharmaceutically acceptable salt thereof, most preferably the acetate salt of the compound, in the treatment of certain diseases and/or conditions such as gastroenterological conditions and/or diseases, such as Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, upper gastrointestinal bleeding, postprandial portal venous hypertension especially in cirrhotic patients, complications of portal hypertension, small bowel! obstruction, gastroesophageal reflux, duodenogastric reflux and in treating endocrinological diseases and/or conditions, such as
Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves’ Disease, diabetic neuropathy, macular degeneration, hypercalcemia of malignancy,
Paget's disease, and polycystic ovary disease; in treating various types of cancer such as thyroid cancer, leukemia, meningioma and conditions associated with cancer such as cancer cachexia; in the treatment of such conditions as hypotension such as orthostatic hypotension and postprandial hypotension and panic attacks. ) Lanreotide is an analog of somatostatin and is known to inhibit growth hormone release as well as inhibit insulin, glucagon and pancreatic exocrine secretion.
U.S. Patent No. 4,853,371 discloses lanreotide, a method for making it and a method for inhibiting the secretion of growth hormone, insulin, glucagon and pancreatic exocrine secretion.
U.S. Patent No. 5,147,856 discloses the use of lanreotide of treating restenosis.
U.S. Patent No. 5,411,943 discloses the use of lanreotide for treating hepatoma.
U.S. Patent No. 5,073,541 discloses the use of lanreotide for treating lung cancer.
U.S. Application No. 08/089,410 filed July 9, 1993 discloses the use of lanreotide for treating melanoma.
U.S. Patent No. 5,504,069 discloses the use of lanreotide for inhibiting the accelerated growth of a solid tumor.
U.S. Application No. 08/854,941 filed May 13, 1997, discloses the use of lanreotide for decreasing body weight.
U.S. Application No. 08/854,943 filed May 13, 1997, discloses the use of lanreotide for treating insulin resistance and Syndrome X.
U.S. Patent No. 5,688,418 discloses the use of lanreotide for prolonging the survival of pancreatic cells.
PCT Application No. PCT/US97/14154 discloses the use of lanreotide for treating fibrosis.
U.S. Application No. 08/855,311 filed May 13, 1997, discloses the use of lanreotide for treating hyperlipidemia.
U.S. Application No. 08/440,061 filed May 12, 1995, discloses the use of lanreotide for treating hyperamylinemia.
U.S. Application No. 08/852,221 filed May 7, 1997, discloses the use of lanreotide for treating hyperprolactinemia and prolactinomas.
The contents of the foregoing patents and applications are incorporated herein by reference.
This invention is directed to a method of treating a disease or condition which comprises administering to a patient in need thereof an effective amount of the compound H-B-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH,, where the two
Cysteines are bonded by a disulfide bond, or a pharmaceutically acceptable salt thereof, wherein the disease or condition is selected from the group consisting of systemic sclerosis, pancreatic pseudocysts, pancreatic ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, hypersecretory diarrhea, scleroderma, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, complications of portal hypertension, small bowel obstruction, duodenogastric reflux, Cushing's
Syndrome, gonadotropinoma, hyperparathyroidism, diabetic neuropathy, macular degeneration, hypercalcemia of malignancy, Paget's disease, meningioma, cancer cachexia, psoriasis, hypotension and panic attacks.
A preferred method of the immediately foregoing method is where the acetate salt of H-B-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH, is administered.
A preferred method of the immediately foregoing method is where the disease or condition is selected from the group consisting of VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, hypersecretory diarrhea, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, especially in cirrhotic patients, complications of portal hypertension, small bowel obstruction, diabetic neuropathy, meningioma and cancer cachexia.
A preferred method of the immediately foregoing method is where the disease or condition treated is selected from the group consisting of ViPoma, nesidoblastosis, hypersecretory diarrhea, irritable bowel syndrome, small bowel obstruction and diabetic neuropathy.
In another aspect, the present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of the acetate salt of H-B-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH, to treat a disease or condition wherein the disease or condition is selected from the group consisting of systemic sclerosis, pancreatic pseudocysts, pancreatic ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison
Syndrome, hypersecretory diarrhea, scleroderma, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, ’ 25 especially in cirrhotic patients, complications of portal hypertension, small bowel obstruction, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, . hyperparathyroidism, diabetic neuropathy, macular degeneration, hypercalcemia of malignancy, Paget's disease, meningioma, cancer cachexia, psoriasis, hypotension and panic attacks.
Lanreotide is readily prepared according to the procedure disclosed in
U.S. Patent No. 4,853,371, or the procedure disclosed in U.S. Patent No. 5,411,943, the teachings of which are incorporated herein by reference.
Lanreotide is currently marketed as the acetate salt in a 30 mg long-acting form and is available from Ipsen Biotech, Paris, France. )
As is well known to those skilled in the art, the known and potential uses of somatostatin are varied and multitudinous. Somatostatin is known to be useful in the treatment of the diseases and/or conditions listed hereinbelow. The varied uses of somatostatin may be summarized as follows: Cushings Syndrome (see
Clark, R.V. et al, Clin. Res. 38, p. 943A, 1990); gonadotropinoma (see Ambrosi
B., et al, Acta Endocr. (Copenh.) 122, 569-576, 1990); hyperparathyroidism (see Miller, D., et al., Canad. Med. Ass. J., Vol. 145, pp. 227-228, 1991); Paget's disease (see, Palmieri, G.M.A,, et al, J. of Bone and Mineral Research, 7, (Suppl. 1), p. S240 (Abs. 591), 1992); VIPoma (see Koberstein, B., et al., Z.
Gastroenterology, 28, 295-301, 1990 and Christensen, C., Acta Chir. Scand. 155, 541-543, 1989); nesidioblastosis and hyperinsulinism (see Laron, Z., Israel
J. Med. Sci., 26, No. 1, 1-2, 1990, Wilson, D.C, Irish J. Med. Sci., 158, No. 1, 31-32, 1989 and Micic, D., et al., Digestion, 16, Suppl. 1.70. Abs. 193, 1990); gastrinoma (see Bauer, F.E., et al., Europ. J. Pharmacol., 183, 55 1990);
Zollinger-Ellison Syndrome (see Mozell, E., et al., Surg. Gynec. Obstet., 170, 476-484, 1990); hypersecretory diarrhea related to AIDS and other conditions (due to AIDS, see Celio, J.P., et al., Gastroenterology, 98, No. 5, Part 2, Suppl.,
A163 1990; due to elevated gastrin-releasing peptide, see Alhindawi, R., et al.,
Can. J. Surg., 33, 139-142, 1990; secondary to intestinal graft vs. host disease, see Bianco J.A., et al, Transplantation, 49, 1194-1195, 1990; diarrhea associated with chemotherapy, see Petrelli, N., et al.,, Proc. Amer. Soc. Clin.
Oncol., Vol. 10, P 138, Abstr. No. 417 1991); irritable bowel syndrome (see
O'Donnell, L.J.D., et al., Aliment. Pharmacol. Therap., Vol. 4., 177-181, 1990); ) pancreatitis (see Tulassay, Z., et al., Gastroenterology, 98, No. 5, Part 2, Suppl.,
A238, 1990); Crohn's Disease (see Fedorak, R.N., et al, Can. J.
Gastroenterology, 3, No. 2, 53-57, 1989); systemic sclerosis (see Soudah, H., et al., Gastroenterology, 98, No. 5, Part 2, Suppl., A129, 1990); thyroid cancer (see
Modigliani, E., et al., Ann., Endocr. (Paris), 50, 483-488, 1989); psoriasis (see
Camisa, C., et al, Cleveland Clinic J. Med., 57 No. 1, 71-76, 1990), hypotension (see Hoeldtke, R.D., et al., Arch. Phys. Med. Rehabil, 69, 895-898, 1988 and Kooner, J.S., et al., Brit. J. Clin. Pharmacol., 28, 735P-736P, 1989); panic attacks (see Abelson, J.L., et al., Clin. Psychopharmacol., 10, 128-132, 1990); sclerodoma (see Soudah, H., et al., Clin. Res., Vol. 39, p. 303A, 1991);
small bowel obstruction (see Nott, D.M., et al., Brit. J. Surg., Vol. 77, p. A691, 1990); gastroesophageal reflux (see Branch, M.S., et al., Gastroenterology, Vol. 100, No. 5, Part 2 Suppl., p. A425, 1991); duodenogastric reflux (see Hasler,
W., et al., Gastroenterology, Vol. 100, No. 5, Part 2, Suppl., p. A448, 1991);
Graves’ Disease (see Chang, T.C., et al., Brit. Med. J., 304, p. 158, 1992); polycystic ovary disease (see Prelevic, G.M., et al., Metabolism Clinical and
Experimental, 41, Suppl. 2, pp 76-79, 1992); upper gastrointestinal bleeding (see Jenkins, S.A., et al., Gut., 33, pp. 404-407, 1992 and Arrigoni, A., et al,
American Journal of Gastroenterology, 87, p. 1311, (abs. 275), 1992); pancreatic pseudocysts and ascites (see Hartley, J.E., et al., J. Roy. Soc. Med., 85, pp. 107-108, 1992); leukemia (see Santini, et al., 78, (Suppl. 1), p. 429A (Abs. 1708), 1991); meningioma (see Koper, JW., et al, J. Clin. Endocr.
Metab., 74, pp. 543-547, 1992); and cancer cachexia (see Bartlett, D.L,, et al.,
Surg. Forum., 42, pp. 14-16, 1991). The contents of the foregoing references are incorporated herein by reference.
Surprisingly, the Applicant has now discovered that lanreotide itself was particularly useful in treating the conditions, disorders and disease noted hereinabove.
The usefulness of lanreotide in the various disclosed new medical uses can be better understood through the results of tests relating to the treatment of upper gastrointestinal bleeding.
Lanreotide or a pharmaceutically-acceptable salt thereof can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual or topical ) 25 routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
® .
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions.
Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as alive oil and com oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria- retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be : manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as coca butter or a suppository wax.
Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.
The dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatmeant. Generally, dosage levels of between 25 pg/kg.day to 100 mg/kg/day of body weight daily are administered as a single dose or divided into multiple doses to humans and other animals, e.g., mammals, to obtain the desired therapeutic effect.
A preferred general dosage range is 250 ng/kg.day to 5.0 mg/kg/day of body weight daily which can be administered as a single dose or divided into multiple doses.
Further, Lanreotide can be administered in a sustained release © composition such as those described in the following patents. Among those formulations, 14-day or 28-day slow release formulations will be preferred. U.S.
®
Patent No. 5,672,659 teaches sustained release compositions comprising
Lanreotide and a polyester. U.S. Patent No. 5,595,760 teaches sustained : release compositions comprising Lanreotide in a gelable form. U.S. Application
No. 08/929,363 filed September 9, 1997, teaches polymeric sustained release
Rk 5 compositions comprising Lanreotide and chitosan. U.S. Application No. 08/740,778 filed November 1, 1996, teaches sustained release compositions comprising Lanreotide and cyclodextrin. U.S. Application No. 09/015,394 filed
January 29, 1998, teaches absorbable sustained release compositions of
Lanreotide. The contents of the foregoing patents and applications are incorporated herein by reference.
The use of immediate or of sustained release compositions depends on the type of indications aimed at. If the indication consists of an acute or over- acute disorder, a treatment with an immediate form will be preferred over the same with a prolonged release composition. On the contrary, for preventive or long-term treatments, a prolonged release composition will generally be preferred.
Typically, to the indication upper gastrointestinal bleeding will correspond an acute or over-acute treatment with a dosage of 80 to 120 ug/day per person during approximately 5 days. After endoscopical treatment, preventive treatment against recurrence can be performed using lanreotide sustained release forms as an adjuvant to usual treatments; for this type of treatment, 14-day sustained release forms with a total dosage of approximately 30 mg lanreotide or 28-day lanreotide forms can be used.
For other indications than upper gastrointestinal bleeding, which correspond rather long term treatments, 14-day sustained release forms with a total dosage of approximately 30 mg lanreclide or 28-day lanrectide forms will be adequate.
Comprises/comprising" when used in this specification is taken to specify the presence of stated features, integers, steps or components but does not preclude the presence or addition of one or more other features, integers, steps ) or components or groups thereof.
Claims (12)
1. Use of a compound H-R3-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH,, where the two Cysteines are bonded by a disulfide bond, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease or condition which is selected from the group consisting of systemic sclerosis, pancreatic pseudocysts, pancreatic ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, hypersecretory diarrhea, scleroderma, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, complications of portal hypertension, small bowel! obstruction, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, diabetic neuropathy, macular degeneration, hypercalcemia of malignancy, Paget's disease, meningioma, cancer cachexia, psoriasis, hypotension and panic attacks. :
2. Use according to claim 1 wherein the compound is the acetate salt of H-B-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH, is administered.
3. Use according to claim 2 wherein the disease or condition is selected from the group consisting of VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, hypersecretory diarrhea, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, especially in cirrhotic patients, complications of portal hypertension, small bowel obstruction, diabetic neuropathy, meningioma and cancer cachexia. =
4. Use according to claim 3 wherein the disease or condition treated is selected from the group consisting of ViPoma, nesidoblastosis, hypersecretory diarrhea, irritable bowel syndrome, small bowel obstruction and diabetic neuropathy.
S. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of the acetate salt of H-B-D-Nal-Cys- Tyr-D-Trp-Lys-Val-Cys-Thr-NH, to treat a disease or condition wherein the disease or condition is selected from the group consisting of systemic sclerosis, pancreatic pseudocysts, pancreatic ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, hypersecretory diarrhea, scleroderma, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, especially in cirrhotic patients, complications of portal hypertension, small bowel obstruction, duodenogastric
PY WP 00/6185 AMENDED PAGE PCT/US99/17294 reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, diabetic neuropathy, macular degeneration, hypercalcemia of malignancy, Paget's disease, meningioma, cancer cachexia, psoriasis, hypotension and panic attacks.
6. Use as claimed in any one of claims 1 to 4, substantially as hereinbefore described or exemplified.
7. Use according to the invention including any new inventive integer or combination of integers, substantially as herein described.
8. A pharmaceutical composition as claimed in claim 5, substantially as hereinbefore described or exemplified.
9. A pharmaceutical composition including any new inventive integer or combination of integers, substantially as herein described.
10. A pharmaceutical composition as claimed in any one of claims 1, 8 and 9 whenever supplied with instructions for the use thereof in treating the disease or condition which is selected from the group consisting of systemic scerosis, pancreatic pseudocysts, pancreatic ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, hypersecretory diarrhea, sceleroderma, irritable bowel syndrome, upper gastrointestinal bleeding, postprandial portal venous hypertension, especially in cirrhotic patients, complications of portal hypertension, small bowel obstruction, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, diabetic neuropathy, macular degeneration, hypercalcemia of malignancy, Paget's disease, meningioma, cancer cachexia, psoriasis, hypotension and panic attacks.
11. A pharmaceutical composition as claimed in claim 10 when the instructions are in printed or written form.
12. A pharmaceutical composition as claimed in claim 11 supplied in a package or container having the said instructions provided therein or thereon.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12652598A | 1998-07-30 | 1998-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200100793B true ZA200100793B (en) | 2001-05-02 |
Family
ID=27733599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200100793A ZA200100793B (en) | 1998-07-30 | 2001-01-29 | Methods of using a somatostatin analogue. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200100793B (en) |
-
2001
- 2001-01-29 ZA ZA200100793A patent/ZA200100793B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU770193B2 (en) | Methods of using a somatostatin analogue | |
US9303067B2 (en) | Sustained release formulation comprising a somatostatin analogue | |
US9119883B2 (en) | Reversible pegylated drugs | |
US7153930B1 (en) | Peptide transport | |
US20080242609A1 (en) | Composition for the therapy of diabetes mellitus and adiposity | |
US20070027073A1 (en) | Long-acting derivatives of pyy agonists | |
US6150333A (en) | Methods of using a somatostatin analogue | |
EP0896544A1 (en) | Combination of a somatostatin analogue and a rapamycin | |
AU2007218297B2 (en) | Combination of Somatostatin-analogs with different selectivity for human Somatostatin receptor subtypes | |
EP1291022A1 (en) | Methods of using lanreotide, a somatostatin analogue | |
ZA200100793B (en) | Methods of using a somatostatin analogue. | |
EP1648934B1 (en) | Pharmaceutical composition comprising cyclic somatostatin analogues | |
EP0657174A1 (en) | Use of somatostatin | |
RU2004121687A (en) | COMPOSITIONS CONTAINING EPOTHYLONS AND THEIR APPLICATION FOR TREATMENT OF A CARCINOID SYNDROME | |
Panzuto et al. | Unlabelled somatostatin analogues in treatment of digestive endocrine tumours | |
US20110319329A1 (en) | Use of somatostatin analogs in cluster headache | |
WO2001000240A2 (en) | Antitumor compound |